SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Video

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Recent Videos
Related Content
First Case of Clade I Mpox Diagnosed in the US

First Case of Clade I Mpox Diagnosed in the US

John Parkinson
November 20th 2024
Article
From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
August 1st 2024
Podcast
COVID and Influenza Vaccinations Well Tolerated Whether Given Simultaneously or Sequentially

COVID and Influenza Vaccinations Well Tolerated Whether Given Simultaneously or Sequentially

Kenneth Bender, PharmD, MA
November 19th 2024
Article
From Pathogen to Infectious Disease Diagnosis

From Pathogen to Infectious Disease Diagnosis

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
July 12th 2024
Podcast
Diagnostic Company is Developing a Point of Need Spatial Multiplexed Test for Avian Influenza in Humans

Diagnostic Company is Developing a Point of Need Spatial Multiplexed Test for Avian Influenza in Humans

John Parkinson
November 14th 2024
Article
Tuberculosis Meningitis in an Immunocompetent Patient

Tuberculosis Meningitis in an Immunocompetent Patient

Laura Walters, DO;Elizabeth Braden, MD;Elizabeth Novick, MD;Nikita Jaggernauth, MD
November 12th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.